{"id":23799,"date":"2018-08-01T17:56:40","date_gmt":"2018-08-01T17:56:40","guid":{"rendered":"https:\/\/backspace.agency\/innventa\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/"},"modified":"2024-08-13T12:25:04","modified_gmt":"2024-08-13T12:25:04","slug":"nitrofinn-important-additional-strenght-to-innventa-portfolio","status":"publish","type":"post","link":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/","title":{"rendered":"NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio"},"content":{"rendered":"<p>NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio<\/p>\n<p>After launching of Serapinn forte\u00ae, Forticolinn\u00ae, Miocytinn\u00ae, Laringinn\u00ae and Rhinosinn\u00ae, Innventa is continuing with fulfillment of ambitious 2018 new products launch plan. On 20th of July 2018 in Serbian pharmacies \u00a0is available new product in Innventa urology portfolio &#8211; Nitrofinn\u00ae.<\/p>\n<p>Nitrofinn\u00ae is currently the only registered Nitrofurantoin on the market, keeping Innventa faitfull to it\u2019s mission: providing inventive pharma solutions to health sector.<\/p>\n<p>Goran Orlic, the general menager of Innventa, stated that introduction of Nitrofinn\u00ae represents important milestone in further strong growth in Innventa sales in Serbia and region.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio After launching of Serapinn forte\u00ae, Forticolinn\u00ae, Miocytinn\u00ae, Laringinn\u00ae and Rhinosinn\u00ae, Innventa is continuing with fulfillment of ambitious 2018 new products launch plan. On 20th of July 2018 in Serbian pharmacies \u00a0is available new product in Innventa urology portfolio &#8211; Nitrofinn\u00ae. Nitrofinn\u00ae is currently the only registered Nitrofurantoin [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":23800,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-23799","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NITROFINN\u00ae - Important additional strenght to Innventa portfolio - INNventa Pharm<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NITROFINN\u00ae - Important additional strenght to Innventa portfolio - INNventa Pharm\" \/>\n<meta property=\"og:description\" content=\"NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio After launching of Serapinn forte\u00ae, Forticolinn\u00ae, Miocytinn\u00ae, Laringinn\u00ae and Rhinosinn\u00ae, Innventa is continuing with fulfillment of ambitious 2018 new products launch plan. On 20th of July 2018 in Serbian pharmacies \u00a0is available new product in Innventa urology portfolio &#8211; Nitrofinn\u00ae. Nitrofinn\u00ae is currently the only registered Nitrofurantoin [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"INNventa Pharm\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/INNventaPharm\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-01T17:56:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-13T12:25:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/innventa-pharm.com\/wp-content\/uploads\/2024\/07\/nitrofinn-pic.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1594\" \/>\n\t<meta property=\"og:image:height\" content=\"1414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"INNventa Pharm\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"INNventa Pharm\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/\"},\"author\":{\"name\":\"INNventa Pharm\",\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/#\\\/schema\\\/person\\\/889b3a72be927cdef8161a4a4995d3b1\"},\"headline\":\"NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio\",\"datePublished\":\"2018-08-01T17:56:40+00:00\",\"dateModified\":\"2024-08-13T12:25:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/\"},\"wordCount\":104,\"publisher\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/innventa-pharm.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/nitrofinn-pic.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/\",\"url\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/\",\"name\":\"NITROFINN\u00ae - Important additional strenght to Innventa portfolio - INNventa Pharm\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/innventa-pharm.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/nitrofinn-pic.png\",\"datePublished\":\"2018-08-01T17:56:40+00:00\",\"dateModified\":\"2024-08-13T12:25:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/innventa-pharm.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/nitrofinn-pic.png\",\"contentUrl\":\"https:\\\/\\\/innventa-pharm.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/nitrofinn-pic.png\",\"width\":1594,\"height\":1414},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/news\\\/nitrofinn-important-additional-strenght-to-innventa-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NITROFINN\u00ae \u2013 Important additional strenght to Innventa portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/\",\"name\":\"INNventa Pharm\",\"description\":\"Innovative Pharma Solutions\",\"publisher\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/#organization\",\"name\":\"INNventa Pharm\",\"url\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/innventa-pharm.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/innventa-favicon-2017.png\",\"contentUrl\":\"https:\\\/\\\/innventa-pharm.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/innventa-favicon-2017.png\",\"width\":512,\"height\":512,\"caption\":\"INNventa Pharm\"},\"image\":{\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/INNventaPharm\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/innventa-pharm.com\\\/en\\\/#\\\/schema\\\/person\\\/889b3a72be927cdef8161a4a4995d3b1\",\"name\":\"INNventa Pharm\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NITROFINN\u00ae - Important additional strenght to Innventa portfolio - INNventa Pharm","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"NITROFINN\u00ae - Important additional strenght to Innventa portfolio - INNventa Pharm","og_description":"NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio After launching of Serapinn forte\u00ae, Forticolinn\u00ae, Miocytinn\u00ae, Laringinn\u00ae and Rhinosinn\u00ae, Innventa is continuing with fulfillment of ambitious 2018 new products launch plan. On 20th of July 2018 in Serbian pharmacies \u00a0is available new product in Innventa urology portfolio &#8211; Nitrofinn\u00ae. Nitrofinn\u00ae is currently the only registered Nitrofurantoin [&hellip;]","og_url":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/","og_site_name":"INNventa Pharm","article_publisher":"https:\/\/www.facebook.com\/INNventaPharm","article_published_time":"2018-08-01T17:56:40+00:00","article_modified_time":"2024-08-13T12:25:04+00:00","og_image":[{"width":1594,"height":1414,"url":"https:\/\/innventa-pharm.com\/wp-content\/uploads\/2024\/07\/nitrofinn-pic.png","type":"image\/png"}],"author":"INNventa Pharm","twitter_card":"summary_large_image","twitter_misc":{"Written by":"INNventa Pharm","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/#article","isPartOf":{"@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/"},"author":{"name":"INNventa Pharm","@id":"https:\/\/innventa-pharm.com\/en\/#\/schema\/person\/889b3a72be927cdef8161a4a4995d3b1"},"headline":"NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio","datePublished":"2018-08-01T17:56:40+00:00","dateModified":"2024-08-13T12:25:04+00:00","mainEntityOfPage":{"@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/"},"wordCount":104,"publisher":{"@id":"https:\/\/innventa-pharm.com\/en\/#organization"},"image":{"@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/innventa-pharm.com\/wp-content\/uploads\/2024\/07\/nitrofinn-pic.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/","url":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/","name":"NITROFINN\u00ae - Important additional strenght to Innventa portfolio - INNventa Pharm","isPartOf":{"@id":"https:\/\/innventa-pharm.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/innventa-pharm.com\/wp-content\/uploads\/2024\/07\/nitrofinn-pic.png","datePublished":"2018-08-01T17:56:40+00:00","dateModified":"2024-08-13T12:25:04+00:00","breadcrumb":{"@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/#primaryimage","url":"https:\/\/innventa-pharm.com\/wp-content\/uploads\/2024\/07\/nitrofinn-pic.png","contentUrl":"https:\/\/innventa-pharm.com\/wp-content\/uploads\/2024\/07\/nitrofinn-pic.png","width":1594,"height":1414},{"@type":"BreadcrumbList","@id":"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/innventa-pharm.com\/en\/"},{"@type":"ListItem","position":2,"name":"NITROFINN\u00ae \u2013 Important additional strenght to Innventa portfolio"}]},{"@type":"WebSite","@id":"https:\/\/innventa-pharm.com\/en\/#website","url":"https:\/\/innventa-pharm.com\/en\/","name":"INNventa Pharm","description":"Innovative Pharma Solutions","publisher":{"@id":"https:\/\/innventa-pharm.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/innventa-pharm.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/innventa-pharm.com\/en\/#organization","name":"INNventa Pharm","url":"https:\/\/innventa-pharm.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/innventa-pharm.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/innventa-pharm.com\/wp-content\/uploads\/2023\/03\/innventa-favicon-2017.png","contentUrl":"https:\/\/innventa-pharm.com\/wp-content\/uploads\/2023\/03\/innventa-favicon-2017.png","width":512,"height":512,"caption":"INNventa Pharm"},"image":{"@id":"https:\/\/innventa-pharm.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/INNventaPharm"]},{"@type":"Person","@id":"https:\/\/innventa-pharm.com\/en\/#\/schema\/person\/889b3a72be927cdef8161a4a4995d3b1","name":"INNventa Pharm"}]}},"_links":{"self":[{"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/posts\/23799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/comments?post=23799"}],"version-history":[{"count":1,"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/posts\/23799\/revisions"}],"predecessor-version":[{"id":23927,"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/posts\/23799\/revisions\/23927"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/media\/23800"}],"wp:attachment":[{"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/media?parent=23799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/categories?post=23799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/innventa-pharm.com\/en\/wp-json\/wp\/v2\/tags?post=23799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}